Antiphospholipid Syndrome Collaborative Registry (APSCORE)

Completed

• Conditions: Antiphospholipid Syndrome

• Registration Number: NCT00076713
• Lead Sponsor: University of North Carolina, Chapel Hill

Brief Summary

Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. Patients with these antibodies may experience miscarriages and blood clotting disorders, including heart attacks and strokes. APS may occur in people with systemic lupus erythematosus and other autoimmune diseases, or in otherwise healthy individuals.

The Antiphospholipid Syndrome Collaborative Registry (APSCORE) is a national registry and tissue repository for patients with APS. This registry will collect clinical information and blood samples from people with APS.

Detailed Description

Registry participants will have a blood sample drawn and will be interviewed about their medical histories. Participants will be asked to return for a follow-up visit after two years. Clinical, demographic, and laboratory data will be collected. Registry resources will be made available to researchers and medical practitioners to support a broad range of research on the causes, diagnosis, mechanisms, and treatment of APS.

The University of North Carolina at Chapel Hill is the coordinating center and an enrollment site for the registry. There are seven other enrollment sites: Ball Memorial Hospital, Muncie, IN; Duke University, Durham, NC; Hospital for Special Surgery, New York, NY; Johns Hopkins University, Baltimore, MD; Morehouse School of Medicine, Atlanta, GA; University of Texas Health Science Center, San Antonio, TX; and University of Utah Health Science Center, Salt Lake City, UT.

Study Timeline

• Study Start: 2000-04
• Study First Submitted: 2004-02-02
• Study First Submitted QC: 2004-02-02
• Study First Posted: 2004-02-03
• Primary Completion: 2007-04
• Study Completion: 2007-04
• Status Verified: 2013-02
• Last Update Submitted: 2013-02-11
• Last Update Posted: 2013-02-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 860

Inclusion Criteria

• Antiphospholipid antibodies with or without associated clinical manifestations

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (7)

Morehouse School of Medicine; 🇺🇸 Atlanta, Georgia, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Hospital for Special Surgery, Weill-Cornell University Medical Center; 🇺🇸 New York, New York, United States

Johns Hopkins University; 🇺🇸 Baltimore, Maryland, United States

University of North Carolina at Chapel Hill; 🇺🇸 Chapel Hill, North Carolina, United States

University of Texas Health Science Center; 🇺🇸 San Antonio, Texas, United States

University of Utah Health Science Center; 🇺🇸 Salt Lake City, Utah, United States